Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

This finding not only provides a new treatment option for patients with bronchiectasis but also lays a solid foundation for the development of more targeted therapies in the future. This study ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis ...

Metersky concludes, "This is a very promising new treatment and likely will be the first-ever FDA-approved treatment for ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of brensocatib, administered once daily for 24 weeks, prolonged the time to the first ...

Bronchodilators have a limited role in bronchiectasis management compared ... making antibiotics a mainstay of treatment. Augmented mucus clearance is a crucial complementary approach.

"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...

Verona continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine for the ...

Drug developer Insmed has filed a new drug application with the FDA based on the data with hopes that brensocatib could become the first approved treatment for patients with bronchiectasis as well ...